In vivo histone protein acetylation in AML patient cells 4 hours after depsipeptide treatment
Patient no. . | Relative increase in H4 acetylation, % before treatment . | Relative increase in H3 acetylation, % before treatment . | Maximum reduction in bone marrow blast count . |
|---|---|---|---|
| 8 | 160 | 380 | NA |
| 9 | 200 | 340 | NA |
| 10 | 100 | 290 | NA |
| 12 | 340 | 550 | NA |
| 13 | 330 | 330 | NA |
Patient no. . | Relative increase in H4 acetylation, % before treatment . | Relative increase in H3 acetylation, % before treatment . | Maximum reduction in bone marrow blast count . |
|---|---|---|---|
| 8 | 160 | 380 | NA |
| 9 | 200 | 340 | NA |
| 10 | 100 | 290 | NA |
| 12 | 340 | 550 | NA |
| 13 | 330 | 330 | NA |
Data are shown as percentage relative to the pretreatment sample in each case, set at 100%. Increases of at least 100% over the pretreatment sample (ie, 200% or greater) are considered to meet the MEPD criteria. NA indicates no decrease in percentage of bone marrow blast at any time point evaluated.